Shiyao Group (01093): Phase II clinical trial of SYH2062 injection for the treatment of essential hypertension in adults officially launched at the first center in China

Zhitongcaijing · 3d ago

Zhitong Finance App News, Shiyao Group (01093) announced that the phase II clinical trial (SYH2062-003) of the SYH2062 injection developed by the group to treat essential hypertension in adults has been officially launched at the first center in China.

This product is a chemically modified double chain small interfering ribonucleic acid (siRNA) with a length of 21 to 23 nucleotides. N-acetylgalactosamine (GalNAc) coupling technology is used to achieve targeted liver delivery. This product can specifically silence the angiotensinogen (AGT) gene, inhibit the expression of corresponding proteins, and relieve excessive activation of the renin-angiotensin system (RAAS), thereby exerting effective pathway inhibition and long-term blood pressure control effects.

Previously, the product had obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration of the People's Republic of China in December 2024. At present, the Group has obtained phase I clinical trial data in hypertensive patients, and has initially verified its safety and pharmacokinetic characteristics in humans. The product is expected to bring longer-lasting and more stable antihypertensive benefits to adult Chinese patients with essential hypertension.

This phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the product in subjects with mild to moderate essential hypertension. Currently, the recruitment and screening of test subjects is being actively promoted.